Meperidine

Meperidine

SCHEMBL3054250

CCOC(=O)C1(c2ccccc2)CCN(C)CC1.[Cl-].[H+]

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1

The experimentally established mechanism targets of Meperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
OPRM1 known ✓ P35372 10/20 0.94
OPRD1 P41143 4/20 0.94
OPRK1 P41145 4/20 0.94
SLC22A1 O15245 1/20 0.94
SLC6A4 P31645 1/20 0.94
ADRA1A P35348 1/20 0.94
KCNH2 Q12809 1/20 0.94

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Meperidine SCHEMBL25431 0.97 OPRM1 (1.00) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL28905219 0.96 OPRM1 (0.97) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL41046 0.96 OPRM1 (1.00) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL27945061 0.96 OPRM1 (0.97) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL2860723 0.96 OPRM1 (1.00) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL1083668 0.96 OPRM1 (1.00) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL194412 0.96 OPRM1 (1.00) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL28695347 0.94 OPRM1 (0.94) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Ethoheptazine SCHEMBL24581 0.92 OPRM1 (0.90) OPRM1OPRD1OPRK1SLC22A1SLC6A4
Meperidine SCHEMBL12574647 0.88 OPRM1 (0.82) OPRM1OPRD1OPRK1SLC22A1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101896161-A Solid formulations of crystalline compounds PURDUE RESEARCH FOUNDATION 2010-11-24 CN disclosed
US-20100222311-A1 SOLID FORMULATIONS OF CRYSTALLINE COMPOUNDS PURDUE RESEARCH FOUNDATION (US) 2010-09-02 US disclosed
EP-2021502-A1 NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY Oy Jurilab Ltd (FI) 2009-02-11 EP disclosed
CN-100438873-C Application of tetrodotoxin as analgesic tolerance inhibitor in preparation of compound pain relieving preparation ZHIQIANG HUANG (CN) 2008-12-03 CN disclosed
WO-2007128884-A1 NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY OY JURILAB LTD (FI) 2007-11-15 WO disclosed
CN-101031298-A Medicine with analgesic effect WANG JIANSHENG (CN) 2007-09-05 CN disclosed
CN-1968694-A An analgesic pharmaceutical composition WANG JIANSHENG (CN) 2007-05-23 CN disclosed
CN-1864685-A Application of tetrodotoxin as analgesic tolerance inhibitor in preparation of compound pain relieving preparation HUANG ZHIQIANG (CN) 2006-11-22 CN disclosed
CN-1194693-C Application of paralytic PSP toxin in preparing antalgesic medicine INST OCEANOLOGY CHINESE ACADEM (CN) 2005-03-30 CN disclosed
CN-1485036-A Compound demerol formulation 广州贝氏药业有限公司 2004-03-31 CN disclosed
CN-1468597-A Continuous released medical composition F.H.福尔丁有限公司 2004-01-21 CN disclosed